ArticlePediatric surgery international2025
Approach to biliary tree clearance in pediatric patients undergoing cholecystectomy: insights from a tertiary hospital.
Article in Pediatric surgery international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDespite the increasing rate of cholecystectomy in pediatric patients, no standardized protocols for perioperative biliary tree clearance in children exist and the applicability of adult guidelines to pediatric patients remains uncertain.
aimTo identify predictors for CBD stones in pediatric patients undergoing cholecystectomy and to evaluate the applicability of adult guidelines for children. MATERIALS AND
methodsWe conducted a retrospective study on pediatric patients who underwent cholecystectomy for cholelithiasis at a tertiary pediatric medical center from 2011 to 2024. Medical records were reviewed for demographic and clinical characteristics. Elevated bilirubin was defined as above 4 mg/dL with > 20% conjugated. The outcomes measured included the presence of CBD stones detected by ERCP or intraoperative cholangiography and post-cholecystectomy complications due to retained stones.
resultsA total of 177 patients were included in the study, with a median age of 13.4 years (IQR 9, 16.4). Sixteen patients (9%) were diagnosed with CBD stones. Elevated bilirubin, dilated CBD, and filling defects on primary imaging were strongly associated with CBD stones (50.0% vs. 9.9%, p < 0.001, 62.5% vs. 9.3%, p < 0.001, 43.8% vs. 4.4%, p < 0.001). The 2019 ASGE guidelines had a sensitivity of 56.2% and a specificity of 91.1% for predicting CBD stones. Adjusting the guidelines to classify elevated bilirubin as an independent high-risk feature improved sensitivity to 68.8%, with a slight reduction in specificity to 87.6%.
conclusionOur study suggests that the 2019 ASGE guidelines are applicable to children. Based on our findings and previous data, it seems reasonable to classify bilirubin elevation as an independent high-risk feature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.